Magic Genomix developed an AI software based on 2 innovative bio markers : the one linked to the transcription
and one linked to the replication.
Our product Magic X is especially dedicated for complex genomics cancer, with limited treatment options and poor prognoses, such as Soft Tissue Sarcoma.
At Magic Genomix, we believe that genomic instability is part of the solution to better predict and personalized treatment for each patient. The distribution of the genomic instability and especially its concentration could be predictive of the response to treatment.
From the biopsy of the tumour and the DNA sequencing after the mutation detection, our software is able to calculate the impactful concentration thresholds that determine the good responders.
Personalized medicine must become a reality for patients, oncologists, researchers, and the entire drug discovery industry. This is our daily mission, in collaboration with our trusted partners from hospitals and MedTech companies worldwide.
Magic Genomix has been founded by a complementary team of experts in business, AI, and scientific research to streamline the journey towards new and innovative treatments for patients and already received recognition from European founds and French gratification from public bank of innovation.
-
Secteur
-
Laboratoires d’analyses médicales
-
Taille de l’entreprise
-
2-10 employés
-
Siège social
-
Toulouse
-
Type
-
Société civile/Société commerciale/Autres types de sociétés
-
Fondée en
-
2023
-
Domaines
-
Oncolgy , AI, Sofware, Bio Markers, Genomic Instability et Complex cancer